Journal
PEPTIDES
Volume 28, Issue 10, Pages 1998-2003Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2007.07.024
Keywords
opioid peptide; anxiolytic effect; rubisco; dopamine receptor; sigma receptor
Ask authors/readers for more resources
Rubiscolin-6 (Tyr-Pro-Leu-Asp-Leu-Phe) is a opioid peptide derived from the large subunit of spinach D-ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco). We previously reported that rubiscolin-6 had an analgesic effect and stimulated memory consolidation. Here we show that intraperitoneally (i.p.) or orally administered rubiscolin-6 has an anxiolytic effect at a dose of 10 mg/kg or 100 mg/kg, respectively, in the elevated plus-maze test in mice. The anxiolytic effects of rubscolin-6 after i.p. (10 mg/kg) and oral (100 mg/kg) administration were blocked by a 8 opioid receptor antagonist, naltrindole (1 mg/kg, s.c.), suggesting that the anxiolytic activity of rubiscolin-6 is mediated by 6 opioid receptor. The anxiolytic effect of rubiscolin-6 (10 mg/kg, i.p.) was also blocked by a dopamine D, antagonist, SCH23390 (30 mu g/kg, i.p.), but not by a dopamine D-2 antagonist, raclopride (15 mu g/kg, i.p.). The anxiolytic effect of rubiscolin-6 (10 mg/kg, i.p.) was blocked by (T, receptor antagonist, BMY14802 (0.5 mg/kg, i.p.) or BD1047 (10 mg/kg, i.p.). Taken together, the anxiolytic effect of rubiscolin-6 is mediated by sigma(1) and dopamine D-1 receptors downstream of 8 opioid receptor. (C) 2007 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available